×

Loading...
Ad by
  • 最优利率和cashback可以申请特批，好信用好收入offer更好。请点链接扫码加微信咨询，Scotiabank -- Nick Zhang 6478812600。
Ad by
  • 最优利率和cashback可以申请特批，好信用好收入offer更好。请点链接扫码加微信咨询，Scotiabank -- Nick Zhang 6478812600。

@Manitoba

当初默克可是宣布降低住院率或死亡率50%的。把有效的老药说成无效，把无效的新药说成有效，FDA和药厂一起割韭菜。

blueskygg(Grass)
At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died
Full Story:
https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
(#15053252@0)
Last Updated: 2022-12-25
This post has been archived. It cannot be replied.
Report

Replies, comments and Discussions:

  • 枫下家园 / 医药保健 / 默克的新冠药Molnupiravir在前3个季度卖了50亿美元，然而，牛津大学最新试验发现，该药并不能降低住院率或死亡率。 -blueskygg(Grass); 2022-12-25 {568} (#15053166@0) +2
    Molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community.
    Full Story:
    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02597-1/fulltext
    • 谢蓝天同学介绍名牌文章,如果有这药,我会屯点 -xiaozuiba(xiaozuiba); 2022-12-25 {1167} (#15053229@0) +1

      Discussion

      This analysis of the largest randomised trial involving people vaccinated against SARS-CoV-2 infection who are at increased risk of adverse outcomes in the community and unwell with COVID-19 showed that the early addition of molnupiravir to usual care did not reduce hospital admissions or death (which were low in both treatment groups). However, participants in the molnupiravir plus usual care group recovered faster than those in the usual care group, had a higher rate of early sustained recovery, and had fewer general practitioner consultations. This faster patient-reported recovery was consistent with a reduction in detectable virus and viral load in participants who received molnupiravir compared with those who received usual care only. We did not identify any patient subgroup in which molnupiravir was associated with a reduced chance of hospital admission, and benefits in terms of time to first self-report of recovery were evenly distributed across subgroups. We recorded few serious adverse events in the trial, and none definitely related to molnupiravir.

      • 当初默克可是宣布降低住院率或死亡率50%的。把有效的老药说成无效，把无效的新药说成有效，FDA和药厂一起割韭菜。 -blueskygg(Grass); 2022-12-25 {1704} (#15053252@0) +1
        At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died
        Full Story:
        https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
        • 采样对象不同,默克的受试对象至少要有1个危险因素,且年龄不明 -xiaozuiba(xiaozuiba); 2022-12-25 (#15053351@0)
          • 这么说某些人奉若神明的双盲试验也不靠谱，一个做出来降低住院率50%，另一个做出来降低0%。所以要做个试验证明IVM无效那是很容易了。 -blueskygg(Grass); 2022-12-25 (#15054084@0)
            • 对不同对象做双盲实验得到不同的结果很正常 -xiaozuiba(xiaozuiba); 2022-12-26 (#15054622@0)
              • 所以我可以轻易设计一个双盲试验来证明辉瑞新冠药无效，找“合适”的对象，把两种药去掉一种，服用5天改3天等等，那些证明IVM无效的试验就是用的这些方法。 -blueskygg(Grass); 2022-12-26 (#15054842@0)
                • 兽药是否有效的实验做过很多,不同的结果都有人信 -xiaozuiba(xiaozuiba); 2022-12-26 (#15054858@0)
                  • 对IVM，FDA只看无效的结果，有效的结果假装没看见。对默克药，FDA就只看厂家自己做的有效的结果，牛津大学做的无效的结果FDA是不会看见的。 -blueskygg(Grass); 2022-12-26 (#15054916@0)
                • 将所有高龄，感染超过一周并有咳嗽症状选为标的，用辉瑞实验，很容易得出，辉瑞无法阻止病人转为重症，辉瑞药物无效的结论，药物控制都是要早期介入，很重要。IVM就是这么搞掉的。 -lovedrive(深蓝爷爷); 2022-12-26 (#15054918@0)
                  • 或者找身体好症状轻的，吃不吃药都会好，就算早期介入，用药组和对照组也不会有明显区别，结论也是辉瑞药无效。 -blueskygg(Grass); 2022-12-26 (#15054984@0) +1
      • 都过去了真要屯吗 -**🐮; 2022-12-26 (#15054642@0)
        • 用默克药的105人住院，用安慰剂的只有98人住院，这药还不如安慰剂，屯它干啥？ -blueskygg(Grass); 2022-12-26 (#15054851@0) +1
        • 有就屯 -xiaozuiba(xiaozuiba); 2022-12-26 (#15054859@0)
          • 默克这药确实没啥用，还是屯辉瑞的吧，听说辉瑞的可以免费拿了，不知道是真是假 -tzm_oasis(绿洲); 2022-12-26 (#15055008@0)
            • 满足条件的药剂师会直接给药，不用医生处方。不过这药和很多药冲突的，不能同时服用。 -blueskygg(Grass); 2022-12-26 (#15055037@0)
              • 👍 -tzm_oasis(绿洲); 2022-12-26 (#15055067@0)
    • 默克的药刚出来不久就爆出有效性不到30%，而且副作用比较大，当时的新闻到处都是。 -coolrock(coolrock); 2022-12-26 (#15055264@0)
      • FDA门槛咋这么低了？30%都批？那还不如批印度神牛的尿尿。副作用不大，正作用或许也有30%。 -bottom(核桃夹子); 2022-12-26 (#15055289@0)
      • 牛津的研究发现有效率是0。 -blueskygg(Grass); 2022-12-26 (#15055294@0)

More Topics

  • 想买压力袜， 去家附近一个店被告知关了。除了shoppers这种大药店可以买， 请告知哪有保险可以cover的买压力袜 的店, 谢谢!
  • 约翰·坎贝尔博士：COVID 注射不是疫苗，它们是基因制剂，脂质纳米粒子无处不在。这些脂质纳米颗粒被设计成可以穿越细胞膜，可以破坏身体的任何部位👇
  • 路易斯安那州众议院通过了一项决议，呼吁卫生部调查该州过去10年发生的婴儿猝死综合症(sIDS)事件，并将每份报告与儿童的疫苗接种史进行比较。
  • 罗伯特·弗朗西斯·甘迺迪说: “1月20日，特朗普政府将命令美国所有供水系统从公共水中去除氟化物。“氟化物是一种工业废物，与关节炎、骨折、骨癌、智商损失、神经发育障碍和甲状腺疾病有关。”
  • 有没有比较好用和方便的water flosser推荐吗? waterpik那个看上去太大和复杂.
    • 枫下论坛主坛 /  枫下家园 /  医药保健